Benchling Accelerates AI Roadmap with ReSync Bio and Sphinx Bio

San Francisco, CA, August 20, 2025 — Benchling has acquired the teams at ReSync Bio and Sphinx Bio, two startups developing AI tools that power scientific workflows. Together with Benchling, they will help make AI a seamless part of everyday research.

“The biopharma industry spends more than $250 billion per year on R&D, only for most medicines to fail in clinical trials,” said Sajith Wickramasekara, CEO and co-founder of Benchling. “The potential for AI to transform drug discovery is enormous, but largely untapped. The teams at ReSync and Sphinx share our mission to change that. Together we will build tools that can help scientists deliver more therapies to patients, faster.”

When Benchling started over a decade ago, the ecosystem for scientific software was small. Today, it’s grown significantly, with a new generation of founders building for the frontier of biology and AI. ReSync and Sphinx are two industry-leading examples.

• ReSync Bio developed software for R&D teams to manage compute, experiments, and data across the Design-Make-Test-Analyze lifecycle. Initially working in small molecule discovery, ReSync’s platform helped scientists run the latest scientific AI models without building their own compute infrastructure.

• Sphinx Bio built a modern analysis platform for scientists to explore and act on experimental data in real time, eliminating the need for tool-switching or downstream data wrangling.

“At ReSync, we set out to bridge the gap between in silico design and lab execution,” said Mihir Trivedi, founder of ReSync Bio. “We’re thrilled to join Benchling, where we can bring powerful AI models to the hundreds of thousands of scientists who already use the platform every day.”

“At Sphinx, our mission has been to help scientists make better decisions, faster,” said Nicholas Larus-Stone, founder of Sphinx Bio. “Benchling is the best place to carry that work forward. It’s the industry standard for how scientists generate data, analyze results, and move research forward at scale.”

Benchling is actively expanding its AI roadmap, including new AI agents, automation tools, and deeper integrations with AI/ML partners. The Sphinx Bio and ReSync Bio teams strengthen that momentum and deepen Benchling’s bench of R&D-focused builders.

Benchling will share more about its AI roadmap at Benchtalk, the company’s annual summit, taking place this October in Boston and London.

About Benchling

Benchling creates the software that powers the biotechnology industry, serving cutting-edge start-ups and more than half of the top 50 global biopharma companies. Over 200,000 scientists rely on the Benchling R&D Cloud as their central source of truth for scientific data, analysis, and collaboration. With software purpose-built for biology, Benchling is on a mission to unlock the power of biotechnology. To learn more, visit Benchling.com.